Clinical Trial

Immunotherapy in Lymphoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is: Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies? Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes. Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.
Trial Details
NCT Number NCT06796517
Lead Sponsor Sung-Soo Park
Collaborators: Yeouido St. Mary's Hospital
Conditions Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, Primary Mediastinal Large B-Cell Lymphoma, Burkitt Lymphoma
Enrollment 72 participants
Start Date 2024-06-26
Primary Completion 2025-12 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-28